Vasodilating Beta Blockers The New Frontier Abdul H Sankari, MD FACC FCCP.

Slides:

Advertisements

Similar presentations

Vasodilating Versus First- Generation β-blockers for Cardiovascular Protection Scott Morgan MSIII November 2012.

Advertisements

Ronald A. Codario, MD Assistant Clinical Professor of Medicine

The Risk Concept in health care Definition of a risk factor  a disease precursor associated with a higher than average morbidity or mortality rate. John.

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

CHARM Program: 3 Component trials comparing candesartan with placebo.

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

Chapter 9Health Benefits of Physical Activity. Our unhealthy lifestyle We participate in work and leisure activities that are far less active than in.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

What is Diabetes?.

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.

Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.

By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.

Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.

New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology

DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Diabetes Mellitus 101 for Medical Professionals

Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):

Chapter 15 Cardiovascular Disease Risk Factors and Physical Activity.

A Diabetes Outcome Progression Trial

The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.

The University of Wisconsin Medical School The Center for Tobacco Research and Intervention Treating Tobacco Addiction in a Subject concerned about Weight.

Section IV. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension 2015 Canadian Hypertension Education Program Recommendations.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

DIABETIC TEACHING VERMALYNPAULETTEMICHELLEEDWARD.

Evidence Base Medicine Family Practice Michelle Cho.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17,

Preferred Underwriting Milner Internal Training Session.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Holistic Approach For Diabetics Supported by GlucosCare International Pte Ltd.

Background notes Audience: diabetes professional (entry level), patients with diabetes First slide: ADD your name/institution ‘Sponge bob’ slide: hemoglobin.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.

Higher Human Biology Unit 2 Physiology & Health KEY AREA 8: Blood Glucose Levels and Obesity.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Baseline characteristics and effectiveness results

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

Copyright © 2002 American Medical Association. All rights reserved.

Supplementary material

Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.

Effect of Metabolic Surgery on diabetes and hypertension

Copyright © 2012 American Medical Association. All rights reserved.

Diabetes Health Status Report

51st Annual Scientific Session for the LIFE Investigators

Dominique Hansen, PhD, FESC

Macrovascular Complications Microvascular Complications

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

Emerging Mechanisms in Glucose Metabolism

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

End point Valsartan, n (%) Placebo, n (%) Hazard ratio (95% CI) P*

Insulin Secretagogues: Sulfonylureas and “Glinides”

These slides highlight a report from a presentation at the European Society of Cardiology 2003 Congress in Vienna Austria, August 30 - September 3, 2003.

What do I remember? What is the effect of chronically elevated blood glucose levels on blood vessels? What cardiovascular diseases are a consequence of.

Lipid Clinic Challenge

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

These slides highlight a Satellite Symposium at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, September 1-5, Originally.

Change in markers of glycometabolism and cardiovascular risk profile.

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Presentation transcript:

Vasodilating Beta Blockers The New Frontier Abdul H Sankari, MD FACC FCCP

Disclosure No major Holdings or Financial Assets in Pharmaceutical Co. Speakers Bureau for Abott Astra-Zeneca Forest Novartis Schering

OBJECTIVES Identify the scope of Hypertensive Heart Disease. Identify the shortcomings of traditional (non-vasodialating Beta Blockers). Identify the advantages of the Vasodialating Beta Blockers.

Beta Blockers The legacy

Beta Blockers INDICATIONS CAD CHF HTN ATRIAL AND VENTRICULAR ARRHYTHEMIAS

Beta Receptors B1 Heart Kidneys Fat cells B2 Lungs Skeletal Muscles Liver/Pancreas

Nebivolol

Vasodilating Beta blockers Better side effect profile Better Tolerability Better efficacy

Side Effects of Traditional Beta Blockers Fatigue Sexual Dysfunction Depression Cold extremities Decrease Exercise Tolerance Metabolic side effects

But WHY? Fatigue / DecreaseExercise Tolerance Reduced CO & SV Increased PVR (at least in the beginning of therapy)

Sexual Dysfunction Decreased blood flow in the Corpora Cavernosa due to Vasoconstriction

Metabolic Changes Increased insulin resistance Lipid Metabolisem

Increased Insulin Resistance Vasoconstriction causes decrease in micro-vascular surface area in skeletal muscle causing reduction in the insulin- mediated glucose entry and metabolism.

Bakris GL. American Heart Association Scientific Sessions Nov 7-10, 2004; New Orleans, LA. GEMINI: Relative to metoprolol, treatment with carvedilol stabilized hemoglobin A1c (HbA1c), a measure of glycemic control; improved insulin resistance; and slowed the development of microalbuminuria. End pointMetoprololpCarvedilolp Mean HbA1c change with treatment, % (SD) 0.15 (0.04)< (0.04)0.65 Insulin sensitivity (%)

GEMINI: Progression to microalbuminuria Bakris GL. American Heart Association Scientific Sessions Nov 7-10, 2004; New Orleans, LA. End pointMetoprololCarvedilolOdds ratio (95% CI) p Progression to microalbuminuria (%)

Lipid Metabolisem Decreased Lipoprotein Lipase activity results in Increased LDL and Triglyceride levels, and decreased HDL.

Vasodilating Beta Blockers Improved Efficacy in CHF in Elderly and Obese Patients

COMET Trial Results End pointCarvedilol (n=1511) (%) Metoprolol (n=1518) (%) HR (95% CI) p All-cause mortality ( ) All-cause mortality or all-cause hospitalization ( ) Poole-Wilson P. European Heart Failure 2003 meeting; June 21-24, 2003; Strasbourg, France.

Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS) European Society of Cardiology Congress 2004

Main results of SENIORS trial Coats A. European Society of Cardiology Congress 2004; August 28-September 1, 2004; Munich, Germany. End pointNebivolol, n (%) Placebo, n (%) Hazard ratio (95% CI) p All-cause mortality/ cardiovascular hospitalizations 332 (31.1)375 (35.3) 0.86 ( ) All-cause mortality 169 (15.8)192 (18.1) 0.88 ( ) 0.214

SIGNIFICANT NOTE around one third of heart-failure patients are actually receiving BB in clinical practice, because clinical trials have generally included younger patients (average age 61), whereas the average age of heart-failure patients in the real world was 76.

Elderly Patients Decreased density of Beta receptors results in decreased efficacy in the elderly. Vasodilating BB do not just work by blocking the Beta Receptors.

Obese patients Traditional Beta Blockers results in 1.2 Kg/Yr weight gain due to reduced resting energy expenditure, and thermogenesis (by as much as 10% in some trials).